Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management

Zain, Jasmine; Hanona, Paul

doi:10.1002/ajh.26270

Cited by 24 publications

(19 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bone marrow transplantation is performed to treat a variety of hematological diseases ( Garcia-Manero et al., 2020 ; Zain and Hanona, 2021 ), but it causes immunosuppression and promotes opportunistic infections, including HCMV, the most fatal ( Ljungman et al., 2011 ). Antiviral agents ( Hodowanec et al., 2020 ) are used to suppress HCMV reactivation, but this has disadvantages ( Koval, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Early immune surveillance to predict cytomegalovirus outcomes after allogeneic hematopoietic stem cell transplantation

Xia

Li²,

Gui³

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundThere is no method of predicting human cytomegalovirus (HCMV) outcomes in allogeneic hematopoietic stem cell transplant recipients clinically, leading in some cases to excessive or insufficient antiviral therapy. We evaluated the early immune response of recipients with disparate HCMV outcomes.MethodsThe HCMV outcomes of recipients were determined by long-term monitoring of HCMV DNA levels posttransplant. HCMV IgG and IgM concentrations at 1 week before and 1 week after transplantation, absolute lymphocyte counts, and HCMV-specific IFN-γ secreting cells at 1 month posttransplant were evaluated based on HCMV outcome.ResultsAll recipients were negative for HCMV IgM. Significant differences between recipients with and without HCMV reactivation were observed in pre- and post-transplant HCMV IgG antibody levels, absolute lymphocyte counts, and HCMV-specific IFN-γ secreting cells (P < 0.05). HCMV IgG antibody levels significantly increased after transplantation in recipients with HCMV reactivation (P = 0.032), but not in those without reactivation. Multivariate analysis revealed that except for the absolute lymphocyte count these biomarkers were related to HCMV reactivation, independent of other clinical factors. In time-to-event analyses, lower levels of these biomarkers were associated with an increased 150-day cumulative incidence of HCMV reactivation (log-rank P < 0.05). In recipients with HCMV reactivation, the duration of HCMV DNAemia had negative correlation with HCMV-specific IFN-γ-secreting cells (P = 0.015, r = -0.372). The relationships between the peak HCMV DNA load and absolute lymphocyte count and HCMV-specific IFN-γ-secreting cells followed the same trends (P = 0.026, r = -0.181 and P = 0.010, r = -0.317).ConclusionsHCMV IgG, absolute lymphocyte count, and HCMV-specific IFN-γ secreting cells represent the humoral and cellular immune response. Early monitoring of these immune markers could enable prediction of HCMV outcomes posttransplant and assessment of the severity of HCMV DNAemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Early immune surveillance to predict cytomegalovirus outcomes after allogeneic hematopoietic stem cell transplantation

Xia

Li²,

Gui³

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Peripheral T-cell lymphoma (PTCL) is a group of lymphoproliferative disorders, originating from mature T/NK cells with highly heterogeneous, aggressive characteristics and poor prognosis. There are 27 subtypes of PTCL in the World Health Organization 2016 classification of lymphoid neoplasm, including extranodal NK/Tcell lymphoma, nasal-type (ENKTL), nonspecific (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase (ALK)+/− anaplastic large cell lymphoma (ALCL) [155,156]. CHOP-based regimens are the first-line treatments for PTCL other than NK/T-cell lymphoma, but the efficacy is limited [157,158].…”

Section: Immune Checkpoints Inhibitors In T-non-hodgkin Lymphomamentioning

confidence: 99%

Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Huang¹,

Huang²

2023

Immune Checkpoint Inhibitors - New Insights and Recent Progress

View full text Add to dashboard Cite

Lymphoma, which mainly includes Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL), is the most common hematological malignance of the lymphoid tissues with significantly heterogeneous characteristics. Tumor immune disequilibrium is involved in tumor development and progression, evading tumor immunosurveillance and suppressing anti-tumor immune responses. The tumor microenvironment (TME) is a complex network that comprises stromal cells and extracellular matrix, playing important roles in the pathogenesis, progression, and drug resistance of lymphoma. Therefore, a promising therapeutic strategy for lymphoma is by targeting the TME to stimulate anticancer immunity either by enhancing the release of immunostimulatory molecules or by mediating immune cell populations. Notably, immune checkpoint therapy (ICT) can provide durable clinical responses and improve overall survival in HL and NHL. However, different subsets of patients with lymphoma have different responses to ICT. Thus, significant challenges remain, including understanding pathways of resistance, optimizing patient selection, improving the management of immune-related adverse events, and identifying rational therapeutic combinations. This will allow a better understanding of the potential applications of ICT in lymphoma, guiding decisions to develop novel combination strategies with maximum efficacy and minimal toxicities for patients.

show abstract

“…Although HTLV-1 is causally linked to ATLL, the long latency period indicates HTLV-1 infection alone is insufficient to induce neoplastic transformation. Only 2.5% of infected individuals are at risk of developing ATLL [ 15 , 18 ]. ATLL shows frequent gain-of-function alterations in the TCR/nuclear factor kappa-light-chain-enhancer of the activated B-cells (NF-kB) signaling pathway [ 19 ].…”

Section: Mature T-cell Lymphomas With Leukemic Presentationmentioning

confidence: 99%

Genetic Landscape of Peripheral T-Cell Lymphoma

Hathuc

Kreisel

2022

Life

View full text Add to dashboard Cite

Peripheral T-Cell lymphoma (PTCL) comprises a heterogenous group of uncommon lymphomas derived from mature, post-thymic or “peripheral” T- and natural killer cells. The World Health Organization (WHO) emphasizes a multiparameter approach in the diagnosis and subclassification of these neoplasms, integrating clinical, morphologic, immunophenotypic, and genetic features into the final diagnosis. Clinical presentation is particularly important due to histologic, immunophenotypic and genetic variations within established subtypes, and no convenient immunophenotypic marker of monoclonality exists. In recent years, widespread use of gene expression profiling and next-generation sequencing (NGS) techniques have contributed to an improved understanding of the pathobiology in PTCLs, and these have been incorporated into the 2016 revised WHO classification of mature T- and NK-cell neoplasms which now encompasses nearly 30 distinct entities. This review discusses the genetic landscape of PTCL and its role in subclassification, prognosis, and potential targeted therapy. In addition to discussing T-Cell lymphoma subtypes with relatively well-defined or relevant genetic aberrancies, special attention is given to genetic advances in T-Cell lymphomas of T follicular helper cell (TFH) origin, highlighting genetic overlaps between angioimmunoblastic T-Cell lymphoma (AITL), follicular T-Cell lymphoma, and nodal peripheral T-Cell lymphoma with a TFH phenotype. Furthermore, genetic drivers will be discussed for ALK-negative anaplastic large cell lymphomas and their role in differentiating these from CD30+ peripheral T-Cell lymphoma, not otherwise specified (NOS) and primary cutaneous anaplastic large cell lymphoma. Lastly, a closer look is given to genetic pathways in peripheral T-Cell lymphoma, NOS, which may guide in teasing out more specific entities in a group of T-Cell lymphomas that represents the most common subcategory and is sometimes referred to as a “wastebasket” category.

show abstract

Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management

Cited by 24 publications

References 131 publications

Early immune surveillance to predict cytomegalovirus outcomes after allogeneic hematopoietic stem cell transplantation

Early immune surveillance to predict cytomegalovirus outcomes after allogeneic hematopoietic stem cell transplantation

Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Genetic Landscape of Peripheral T-Cell Lymphoma

Contact Info

Product

Resources

About